BARINTHUS BIOTHERAPEUTICS PLC - AMERICAN DEPOSITAR

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

12 6 2024 15:01:00 提供 Nasdaq GlobeNewswire

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

06 6 2024 10:15:00 提供 Nasdaq GlobeNewswire

Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

22 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

13 5 2024 07:00:01 提供 Nasdaq GlobeNewswire

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

01 5 2024 06:00:01 提供 Nasdaq GlobeNewswire

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

18 4 2024 15:10:00 提供 Nasdaq GlobeNewswire

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

20 3 2024 07:15:23 提供 Nasdaq GlobeNewswire

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

05 1 2024 15:01:00 提供 Nasdaq GlobeNewswire

New partnership aims to advance vaccine against MERS coronavirus

21 12 2023 06:31:16 提供 Nasdaq GlobeNewswire

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

09 11 2023 15:24:43 提供 Nasdaq GlobeNewswire

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

09 11 2023 15:01:00 提供 Nasdaq GlobeNewswire

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

06 11 2023 08:05:56 提供 Nasdaq GlobeNewswire

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

13 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

10 8 2023 07:00:01 提供 Nasdaq GlobeNewswire

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

21 6 2023 08:03:54 提供 Nasdaq GlobeNewswire

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

12 6 2023 06:30:00 提供 Nasdaq GlobeNewswire

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

12 5 2023 07:00:57 提供 Nasdaq GlobeNewswire

Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile

17 4 2023 08:00:00 提供 Nasdaq GlobeNewswire

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

28 3 2023 07:00:11 提供 Nasdaq GlobeNewswire

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

24 3 2023 07:06:29 提供 Nasdaq GlobeNewswire